Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Optimal management of Barrett's esophagus without high-grade dysplasia

Publish date:: January 10, 2020

Key clinical point: In patients with Barrett’s esophagus and low-grade dysplasia confirmed by repeat endoscopy, endoscopic eradication therapy is the optimal cost-effective management strategy. For patients with nondysplastic Barrett’s esophagus, the optimal surveillance interval is every 3 years for men and every 5 years for women.

Major finding: This strategy decreased esophageal adenocarcinoma incidence by 66% and mortality by 81%, compared with natural history.

Study details: A cost-effectiveness analysis using three population-based models.

Disclosures: The National Institutes of Health/National Cancer Institute supported the study and provided funding for the authors.

Citation:

Omidvari A-H et al. Clin Gastroenterol Hepatol. 2019 Dec 6. doi: 10.1016/j.cgh.2019.11.058.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,